Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Study Finds That Cannabis Use by Adolescents Doesn’t Affect Their Future Success

New research has found that the future success of adolescents who use amphetamines and marijuana will not be adversely affected if they quit the habit before hitting age 30. The study found that people who stopped using these drugs in early adulthood didn’t have lower life quality or relationship or economic success.

The authors of the study explained that amphetamine and marijuana use and/or use disorder in adolescence didn’t appear to doom life success for individuals in adulthood, particularly for those who ceased using the drugs before the age of 30.

The findings of this study were published I”n Addiction Research & Theory.”

The researchers’ study objective was to find the extent to which the use of amphetamines and marijuana up to age 21 forecasted life success for an individual at age 30. Onset use in those who took part in the study ranged between 15 and 19 years.

For their study, the researchers utilized data from more than 2,300 children in Australia who were born to mothers who took part in the Mater-University of Queensland pregnancy study. These children were tested for delinquency/aggression, mental health and IQ at age 14. They were also interviewed at 21, where they self-reported their use of amphetamines and marijuana. They self-reported their use once more at age 30.

Researchers also carried out a composite measure of life success at age 30. This measure considered quality of intimate relationships, quality of life and socioeconomic status. Their findings showed that at 21 years, problematic marijuana use was lower at 18%, with 3% admitting to problematic use of both marijuana and amphetamines and 0.8% reporting only problematic amphetamine use.

With regard to those who reported problematic substance use, these issues persisted at age 30 for 60% of those on both marijuana and amphetamines and more than 35% of those who used marijuana.

In their report, the researchers noted that behavior problems in adolescence predicted drug use at age 21 as well as life success and drug use at age 30. The researchers also discovered a link between early-age onset use of amphetamines, marijuana or both, noting that concurrent use of marijuana at the age 30 follow up was strongly associated with life success.

In their report, the researchers also argued that prior research, which suggested that early-age onset of using these substances led to adverse outcomes when an individual was older, didn’t consider the possibility that it was the subsequent use of drugs which forecasted success in adult life.

As more research is conducted on actual products manufactured by licensed companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), many more misconceptions about the herb may be unveiled.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — California Bill Hopes to End Employment Discrimination Against Cannabis Users

A new bill introduced to the California Assembly seeks to bring an end to employment discrimination against cannabis consumption outside work. Assembly Member Bill Quirk (D–CA) introduced the AB 2188 bill on Feb. 15, 2022, to stop discrimination based on testing of cannabis metabolites, which can be found in a consumer’s body fluids weeks after consumption.

According to Lauren Mendelsohn, an attorney from California-based Omar Figueroa, the bill would prevent employers from firing or refusing to hire based on a person’s off-duty use or detection of cannabis metabolites found in work-mandated tests. However, the bill exempts employers who are obligated to comply with federal drug-testing mandates. According to Mendelsohn, this applies to employees who are required to carry out such screenings or who would likely lose federal benefits if they failed to comply.

Additionally, the AB 2188 bill does not allow employers to let employees be high while on duty. Mendelsohn notes that employees are not authorized to use or “be impaired by cannabis” while working their shifts.

According to a survey conducted by Cal NORML, about 33% of respondents have been turned down from work because of positive marijuana test. Meanwhile, 60% have stopped using cannabis after drug testing by their employers. The bill has received support from the California chapter of the cannabis advocacy group National Organization for the Reform of Marijuana Laws (Cal NORML). According to a statement from the group, testing of bodily fluids is the most common way that employers will use to discriminate and harass employees who consume cannabis away from work.

Prohibitive cannabis policies rely on nonscientific data, which threaten the liberties of the consumers since the positive drug tests are not an effective method of measuring cannabis-induced impairment while on the job. According to Edward Wicker, the director of San Diego NORML, the bill will bring fairness and offer legal protection that is backed by science to California workers.

Testing for cannabis metabolites is a nonscientific approach because it is not an indication that the employee is impaired from cannabis consumption because a person can have a positive test days or weeks after using cannabis. As a result, Wicker sees that the prevailing use of such tests is for “arbitrary discrimination” purposes.

Moreover, several studies have shown that off-duty use of cannabis has not been linked to an increase in work-related accidents or injuries. According to Cal NORML, jurisdictions with enabling marijuana laws have been linked to higher wages, great workforce participation, reduced absenteeism rates among employees and fewer workers’ compensation claims from workers. All eyes are now on California as other five states including New York, have passed legislation that protects employment rights of cannabis users.

When this bill is passed, California residents will be less uneasy about consuming the cannabis products made by state-legal companies such as American Cannabis Partners since the likelihood of being victimized for off-duty consumption will be reduced.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

ZJ Events Presents Alternative Products Expo to Discuss the Potential of the Alternative Products Ecosystem

Vendors, businesses, industries, CBD & alternative product vendors, researchers, and professionals are invited to attend the Alternative Products Expo at Fort Lauderdale on March 11-13th, 2022. Organized by ZJ Events, the event group is committed to bringing the industry’s best alternative products traders, vendors, and enthusiasts under one platform, while offering a fun and enriching experience.

Alternative Products Expo is evolving to include a wide gamut of products featuring novel products and services that are disrupting traditional markets. Alternative Products Expo strives to bring the best industry products to the consumers while creating networking opportunities for traders and vendors attending the event.

With the fast-growing demand for alternative products, Alternative Products Expo offers a viable platform to grow networking ties and seek guidance from the leading influencers. ZJ Events is a pioneer in organizing top-notch trade shows that are committed to encouraging individual growth and opportunity. It’s worth mentioning that the Fort Lauderdale show quickly sold out in booths, and the upcoming events in Medellin and Tampa are already at an impressive 90% and 40% sold out, respectively!

Attendees can register as exhibitors to showcase their alternative products and services at their respective booths. They can also participate as speakers sharing in-depth insights about the scope and potential of the alternative product ecosystem. The alternative product category includes herbal products, mood enhancers, cannabis derivatives, vape products, energy boost, and dietary supplements, to name.

Alternative Products Expo will feature 50+ speakers per event, 300+ vendors per event, and 1000+ products per event.

Among the sponsors are:

Presenting sponsor – 3Chi #Booth 530
Platinum sponsor – Lost 8’s #Booth 323 & 218
Platinum sponsor – Dimo #Booth 717
Platinum sponsor – Trinity Hemp #Booth 131

The expert panel of speakers:

Keith Villa – CERIA Brewing Company
Durée Ross – Durée & Company
Michael Greico – Florida House of Representatives
Yasmine Egozi – Planta Rx

This 3-day event will open the gates to an extensive array of knowledge and information on the alternative product spectrum. Businesses can also leverage the substantial exclusive opportunity of special pricing and discounts to get the best prices on leading brands.

Influencers and reputed personalities will discuss and share insights about the latest market trends of the growing alternative product ecosystem. The conference is an excellent platform for joint venture collaborations and gives attendees direct access to connect with worldwide cannabis industry leaders.

For more information on purchasing tickets, upcoming events, and discounts, please visit https://altproexpo.com/.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) On Path Toward Improved Margins Through Vertical Integration

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a cannabis and CBD product brand builder with a presence in California, Arizona, Oklahoma, Illinois, Michigan, and Florida, most recently celebrated the news that Michigan had granted it adult recreational use prequalification status for manufacture, followed by full licensing to make both medical and adult-use cannabis products in the state. “The company’s lease assignment for a 15,000-square-foot manufacturing and processing facility in the city of Warren led to the launch of operations there [in January], with ‘all necessary equipment already installed and inspections completed’ for medical and adult-use products,” a recent article reads. “‘This Warren facility allows us to centralize distribution for our’ house of premium brands’ in Michigan and finally report all of our Platinum Vape(TM) wholesale sales on a much less confusing and straightforward basis,’ CEO and Chairman Brad Rogers stated. ‘The facility provides the production capacity to expand sales of our award-winning brands from the 250+ Michigan dispensaries that carry them to the state’s 400+ dispensaries.’… The developments in Michigan are expected to help the company improve its margins through vertical integration of its operations.”

To view the full article, visit https://cnw.fm/PFLRR

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Michigan, Illinois, Massachusetts, Arizona and California with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Completes 1st US Import of CBD Products from Colombia

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced that it has completed its first import of CBD-containing food and beverage products into the United States from Colombia under its Mambe brand. The move comes after Colombian President Ivan Duque signed Resolution 227 last week, providing the necessary framework for the use, distribution and export of cannabis, dried flower and other non-psychoactive derivatives. “We are thrilled to be the first Colombian cannabis operator to capitalize on the law change President Duque signed into effect,” said Flora Growth CEO Luis Merchan. “We are grateful for the Colombian government’s forward-thinking approach to cannabis regulation and are excited to bring Colombian-made cannabis food and beverage products to the U.S. market. Our team anticipated this regulatory update and has been laying the necessary foundation to expand this new supply chain pathway allowing Flora to quickly bring our diverse product portfolio and low-cost cannabis inputs to new high-growth international markets.”

To view the full press release, visit https://cnw.fm/ZK89Q

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — NCAA Committee Makes Recommendation to Increase THC Threshold for Drug Tests

The Committee on Competitive Safeguards and Medical Aspects of Sports under the NCAA recently announced new recommendations which stipulate that student athletes wouldn’t automatically lose their eligibility to play after testing positive for cannabis.

The committee increased the threshold for THC, which constituted a positive test to 150 nanograms (“ng”) per ml from 35 ng per ml. This increase aligns the NCAA’s policy with the World Anti-Doping Agency’s policy. Various discussions on the NCAA’s rules on marijuana have been held by members these past few months. This latest decision is consistent with moves made in different professional sports leagues as more states legalize the herb.

In a press release, the chief medical officer of the NCAA, Brian Hainline, stated that reconsidering the organization’s approach to marijuana testing and management was consistent with member feedback on how to better educate and support student-athletes in a society with evolving cultural and public health views on the use of marijuana. Hainline added that while cannabis wasn’t considered a performance-enhancing substance, it was important for member schools to offer support and management when appropriate and engage student-athletes on substance-use prevention.

The committee stated that there would be no loss of eligibility for first, second and third positive THC tests, as long as the school offered an education and management plan for the student-athlete. However, if the student-athlete did not comply with the management plan after a second violation, a 25% suspension from participation in regular season games was recommended. If the student-athlete suffered a third violation and still did not comply with past education and management plans, they would face a 50% suspension from regular season games but wouldn’t lose eligibility.

Currently, the bylaws for Division I-III student athletes state that a first positive cannabis test immediately makes a player ineligible for 50% of regular season games. A second positive test would result in the suspension of a student athlete for a whole season.

Stephanie Chu, chair of the Committee on Competitive Safeguards and Medical Aspects of Sports, stated that these changes to the organization’s drug testing program were approved after extensive discussion and careful consideration, noting that these adjusted marijuana testing policies created a clear pathway for student athletes to take part in management and education programs specific to their needs.

The three divisions under the NCAA are being urged to adopt these new eligibility recommendations into their bylaws. However, it should be noted that these recommendations aren’t binding.

As more and more sports bodies reform their cannabis laws, we are likely to see marijuana products manufactured by such as Flora Growth Corp. (NASDAQ: FLGC) become commonplace and gain wider acceptance in mainstream society, including among athletes who could benefit from the therapeutic potential of these substances.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — USDA Asks White House to Authorize Large Hemp Survey

Last week the U.S. Department of Agriculture (“USDA”) put out a notice seeking approval from the White House to carry out a survey. The agency plans to partner with the University of Kentucky to conduct this follow-up to the first hemp survey released earlier this year on Feb. 17, 2022. According to the notice, the survey is designed to collect data that will be used to forecast hemp activity as well as provide more information on production practices and costs.

Stakeholders lack consistent knowledge and information to navigate risks within the sector. The main purpose of the survey is meant to create transparency. The hemp market is constantly facing high risks that are changing, which according to the USDA includes limited information on the demand for hemp products.

Currently, stakeholders rely on varying information on quality and costs from several private and local sources. The notice mentions that there has been a continued request for the USDA to provide stakeholders with “consistent unbiased data.

This new survey will focus on economic data collected in 2020 to create awareness on the growing industry as well as respond to different needs identified within the sector. The responses will specifically be used to find out production costs as well as the scope and significance for a market structure.

The department said that the gathered data will be used in rulemaking, resource management and risk management. Stakeholders will also be receiving information on market outlook and worldwide competitiveness. According to a USDA spokesperson, hemp producers will receive the survey through the National Association of State Departments of Agriculture (“NASDA”).

The survey is expected to collect data from 20,000 individuals and is planned to be conducted every year. As part of a current review, interested individuals are allowed to submit feedback on the proposed survey during a period of 30 days.

The agency relies on stakeholder feedback and has used it to make hemp businesses more flexible by aligning their insurance policies to those of other crops. For example, hemp growers could qualify for coverage programs including the Multi-Peril Crop Insurance as a result of the agency’s efforts.

In 2020, the department proposed a survey that would help in developing regulations within the sector. The USDA sought to partner with the University of Kentucky to collect data after marijuana was federally legalized. Last month, the department announced that it would be carrying out a webinar series to provide information on hemp with Cornell University as partner.

According to stakeholders, results from the latest survey have shown a decline in the industry and therefore reforms are still needed to aid in growing the industry.

The entire cannabis industry, including sector actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS), would benefit greatly if marijuana was legalized federally and similar surveys were done by the USDA to promote the growth of the industry.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market

InMed Pharmaceuticals (NASDAQ: INM) is uniquely positioned to leverage the growing worldwide awareness of the potential of cannabinoids and the rising demand for rare cannabinoids. The company has begun this year on a high, following the 2021 acquisition of BayMedica and the launch of cannabicitran (“CBT”) sales. “With the launch of business-to-business sales of CBT in the health and wellness sector, InMed has further expanded its portfolio and its presence in the growing rare cannabinoid market,” reports a recent article. “CBT is the first of several new products InMed is planning to launch in the first half of 2022 in response to growing demand. ‘By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors,’ stated Shane Johnson, SVP and general manager of InMed’s subsidiary and recent acquisition BayMedica… For 2022, InMed expects to build on the successes achieved in 2021, especially the acquisition and integration of BayMedica, to secure consistent revenue growth and further advance its pharmaceutical drug development programs, transitioning to become a leading B2B supplier of rare cannabinoids in the consumer health and wellness market.”

To view the full article, visit https://cnw.fm/H4WEE

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released positive results from an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil as potential use in the management of erectile dysfunction. “A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream. During the animal study, it was determined that in as little as four minutes of dosing, the DehydraTECH formulation of sildenafil delivered 74% more of the PDE5 inhibitor into the bloodstream on average than the concentration-matched, generic control formulation. Within seven minutes, the DehydraTECH-sildenafil formulation achieved a higher average blood level than the generic control reached at any point during the study,” reads a recent article. “The most well-known sildenafil product on the market is Viagra(R). The medication is bioavailable orally at approximately 40%, with the most common complaint by consumers that it is slow to act. The findings of Lexaria’s animal study are a first step to developing faster and better acting sildenafil oral formulations.”

To view the full article, visit https://cnw.fm/KVDQe

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Grapefruit USA Inc. (GPFT) on Track to Secure Approval of Hourglass(TM) NNCP

Grapefruit USA (OTCQB: GPFT), an innovative California-based cannabiotech company, today provided an update on progress with its previously announced Notice of New Cannabis Product (“NNCP”) filed with Health Canada for its patented Hourglass(TM) Time Release THC+CBD infused Topical Delivery Cream. Health Canada is the department of the federal government responsible for national health policy, and its approval of the NNCP will enable Grapefruit to sell its patented Hourglass to licensed retail outlets throughout Canada. According to the update, on Feb. 18, 2022, Grapefruit received an inquiry from Health Canada about the composition of specific Hourglass ingredients. Grapefruit’s timely response was promptly accepted by Health Canada. “We are pleased with the significant progress made on our Health Canada Hourglass approval initiative after successfully responding to Health Canada’s first round of requests for additional information,” said Bradley J. Yourist, Grapefruit’s CEO and co-founder. “We are on track to obtain approval of our Hourglass NNCP. Grapefruit looks forward to bringing the Hourglass THC+CBD product to Canada.”

To view the full press release, visit https://cnw.fm/2redb

About Grapefruit USA Inc.

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. Grapefruit’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. For more information about the company and its operations, visit www.GrapefruitBlvd.com

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.